INVESTIGATIONAL PIPELINE A POWERFUL RESEARCH AND DEVELOPMENT ENGINE
Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, Global Development brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron.
Phase 1
-
ALN-APP1
RNAi therapeutic targeting APP Early-onset Alzheimer’s disease
Neurology General Medicine -
ALN-HSD
RNAi therapeutic targeting HSD17B13 Nonalcoholic steatohepatitis ("NASH")
Immunology & Inflammation General Medicine -
ALN-PNP1
RNAi therapeutic targeting PNPLA3 NASH
General Medicine -
FIANLIMAB
Antibody to LAG-3 Solid tumors and advanced hematologic malignancies
Oncology Hematology -
LINVOSELTAMAB
Bispecific antibody targeting BCMA and CD3 Multiple myeloma
Hematology -
"NEXT GENERATION" COVID ANTIBODIES
Antibodies to SARS-CoV-2 Variants Healthy volunteers
Infectious Diseases General Medicine -
NTLA-20013
TTR gene knockout using CRISPR/Cas9 Transthyretin ("ATTR") amyloidosis
Rare Diseases Hematology -
ODRONEXTAMAB6
Bispecific antibody targeting CD20 and CD3 Certain B-cell malignancies
Oncology Hematology -
REGN4336
Bispecific antibody targeting PSMA and CD3 Prostate cancer
Oncology -
REGN5093
Bispecific antibody targeting two distinct MET epitopes MET-altered advanced NSCLC
Oncology -
REGN5093-M114
Bispecific antibody-drug conjugate targeting two distinct MET epitopes MET overexpressing advanced cancer
Oncology -
REGN5381/REGN9035
Agonist Antibody to NPR1/Reversal Agent to REGN5381 Reversal agent in healthy volunteers
General Medicine -
REGN5459
Bispecific antibody targeting BCMA and CD3 Transplant desensitization in patients with chronic kidney disease
Oncology Hematology -
REGN5668
Bispecific antibody targeting MUC16 and CD28 Platinum-resistant ovarian cancer
Oncology -
REGN5678
Bispecific antibody targeting PSMA and CD28 Prostate cancer
Oncology -
REGN6569
Antibody to GITR Solid tumors
Oncology -
REGN7075
Bispecific antibody targeting EGFR and CD28 Solid tumors
Oncology -
REGN7257
Antibody to IL2Rg Aplastic anemia
Hematology -
REGN7508
Antibody to Factor XI Thrombosis
Hematology -
REGN7999
Antibody to TMPRSS6 Transfusion dependent iron overload
Hematology -
REGN9933
Antibody to Factor XI Thrombosis
Hematology
Phase 2
-
CEMIPLIMAB
Antibody to PD-1 Neoadjuvant CSCC; Second-line cervical cancer, ISA101b combination
Oncology -
LINVOSELTAMAB
Bispecific antibody targeting BCMA and CD3 Multiple myeloma (pivotal study)
Oncology Hematology -
MIBAVADEMAB
Agonist antibody to leptin receptor ("LEPR") Generalized lipodystrophy; Partial lipodystrophy
Rare Diseases General Medicine -
ODRONEXTAMAB6
Bispecific antibody targeting CD20 and CD3 B-cell non-Hodgkin lymphoma ("B-NHL") (pivotal study)
Oncology Hematology -
POZELIMAB
Antibody to C5; studied as monotherapy and in combination with cemdisiran CD55-deficient protein-losing enteropathy ("CHAPLE"), monotherapy (potentially pivotal study)
Rare Diseases Hematology -
REGN5381/REGN9035
Agonist Antibody to NPR1/Reversal Agent to REGN5381 Heart failure
General Medicine -
SARILUMAB5
Antibody to IL-6R Polyarticular-course juvenile idiopathic arthritis ("pcJIA"); systemic juvenile idiopathic arthritis ("sJIA")
Immunology & Inflammation -
UBAMATAMAB
Bispecific antibody targeting MUC16 and CD3 Platinum-resistant ovarian cancer
Oncology -
VIDUTOLIMOD
Immune activator targeting TLR9 Solid tumors
Oncology
Phase 3
-
AFLIBERCEPT 8MG2
VEGF-Trap Wet AMD, DME
Ophthalmology -
AFLIBERCEPT2
VEGF-Trap ROP
Ophthalmology -
ALIROCUMAB
Antibody to PCSK9 HeFH in pediatrics
General Medicine -
CEMIPLIMAB
Antibody to PD-1 Adjuvant CSCC
Oncology -
DUPILUMAB5
Antibody to IL-4R alpha subunit EoE in pediatrics; chronic obstructive pulmonary disease ("COPD"); bullous pemphigoid (Phase 2/3); chronic spontaneous urticaria ("CSU"); chronic inducible urticaria - cold; chronic rhinosinusitis without nasal polyposis; allergic fungal rhinosinusitis; chronic pruritis of unknown origin
Immunology & Inflammation -
FIANLIMAB
Antibody to LAG-3 First-line metastatic melanoma; First-line adjuvant melanoma
Oncology -
GARETOSMAB
Antibody to Activin A Fibrodysplasia ossificans progressiva ("FOP")
Rare Diseases General Medicine -
ITEPEKIMAB5
Antibody to IL-33 COPD
Immunology & Inflammation -
POZELIMAB1
Antibody to C5; studied as monotherapy and in combination with cemdisiran Myasthenia gravis, cemdisiran combination; paroxysmal nocturnal hemoglobinuria ("PNH"), cemdisiran combination
Rare Diseases Hematology -
REGN5713-5714-5715
Multi-antibody therapy to Bet v 1 Birch allergy
Immunology & Inflammation
No results found. Please adjust your filter selection and try again.
1In collaboration with Alnylam
2In collaboration with Bayer outside of the U.S.
3In collaboration with Intellia
4In collaboration with Roche outside of the U.S.
5In collaboration with Sanofi
6In collaboration with Zai Lab in mainland China, Hong Kong, Taiwan and Macau
This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.
Scientific trailblazers
Following the science leads to unexpected breakthroughs and diverse areas of study —from ophthalmology to cancer to inflammation to pain to cardiovascular disease.
Our Current Research
Explore our clinical trials
The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. Learn more about our clinical trials or find a relevant one near you.
Find Trialsto top